← All drugs
Drug · FAERS side-effect profile with label screen

Venlafaxine Hydrochloride side effects: what 131,548 FDA adverse event reports show

Venlafaxine Hydrochloride · 1,193 reaction terms · 565,926 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

131,548 reports · 74% serious · 13,161 with death outcome · 72% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Venlafaxine extended-release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder Venlafaxine extended-release tablets are indicated for the treatment of major depressive disorder (MDD).

FDA label, Indications and Usage

What it is

Venlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.

PubChem CID 5656 (ChEBI)

Boxed warning

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 3Labeled adverse reaction 8Labeled (related wording) 3Likely indication confounding 5Not in label — unassessed 21
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,153 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Inspiratory capacity decreased10192.3
72.2–118.0ROR 92.4 · calibrated p 3e-7 ✓
57.8 EB05 48.9 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=101 · ♀ 0% (drug 72%) · 100% clinicianno trial arm names this drug
Amaurosis fugax22241.6
35.9–48.2ROR 41.7 · calibrated p 4e-5 ✓
33.0 EB05 29.5 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=222 · 100% clinicianno trial arm names this drug
Temperature regulation disorder33528.7
25.6–32.3ROR 28.8 · calibrated p 3e-4 ✓
24.4 EB05 22.3 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=328 · ♀ 100% (drug 72%)no trial arm names this drug
Feelings of worthlessness18425.8
22.0–30.1ROR 25.8 · calibrated p 6e-4 ✓
22.2 EB05 19.7 · IC025 +4.2
3/3 methods agree
Likely indication confounding
term in indications
73% consumerno trial arm names this drug
Respiratory disorder neonatal22225.7
22.3–29.6ROR 25.8 · calibrated p 6e-4 ✓
22.2 EB05 19.8 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=222 · ♀ 35% (drug 72%)no trial arm names this drug
Serotonin syndrome2,52024.1
23.1–25.1ROR 24.5 · calibrated p 7e-4 ✓
21.0 EB05 20.3 · IC025 +4.3
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 17.0 · serious PRR 16.3no trial arm names this drug
Hypotonia neonatal19322.9
19.7–26.6ROR 22.9 · calibrated p 0.001 ✓
20.1 EB05 17.8 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=193 · 100% clinicianno trial arm names this drug
Feeling guilty15821.4
18.2–25.3ROR 21.5 · calibrated p 0.002 ✓
18.9 EB05 16.6 · IC025 +3.9
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
100% consumerno trial arm names this drug
Physical deconditioning29821.4
19.0–24.2ROR 21.5 · calibrated p 0.001 ✓
18.9 EB05 17.2 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=298no trial arm names this drug
Bradycardia neonatal14621.0
17.6–24.9ROR 21.0 · calibrated p 0.002 ✓
18.6 EB05 16.2 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=146 · 100% clinicianno trial arm names this drug
Agitation neonatal10920.5
16.8–25.0ROR 20.5 · calibrated p 0.002 ✓
18.2 EB05 15.5 · IC025 +3.8
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=108 · ♀ 0% (drug 72%) · 100% clinicianno trial arm names this drug
Cataplexy16320.4
17.4–24.0ROR 20.5 · calibrated p 0.002 ✓
18.1 EB05 15.9 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=139no trial arm names this drug
Electric shock sensation25116.3
14.3–18.6ROR 16.4 · calibrated p 0.005 ✓
14.9 EB05 13.4 · IC025 +3.6
3/3 methods agree
Labeled adverse reaction
exact term
serious n=206 · 75% consumerno trial arm names this drug
Bezoar11314.2
11.7–17.2ROR 14.2 · calibrated p 0.009 ✓
13.0 EB05 11.1 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=113 · ♀ 100% (drug 72%) · 100% clinicianno trial arm names this drug
Poisoning deliberate74013.7
12.7–14.8ROR 13.8 · calibrated p 0.010 ✓
12.7 EB05 11.9 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious PRR 9.8 · 100% clinicianno trial arm names this drug
Foetal death38812.8
11.6–14.2ROR 12.9 · calibrated p 0.013 ✓
11.9 EB05 10.9 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=388 · ♀ 100% (drug 72%)no trial arm names this drug
Hyperreflexia24511.9
10.5–13.6ROR 12.0 · calibrated p 0.017 ✓
11.1 EB05 10.0 · IC025 +3.2
3/3 methods agree
Labeled adverse reaction
exact term
serious n=243 · 100% clinicianno trial arm names this drug
Emotional poverty11411.0
9.1–13.3ROR 11.0 · calibrated p 0.024 ✓
10.2 EB05 8.7 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=110 · ♀ 0% (drug 72%) · 100% consumerno trial arm names this drug
Derealisation13410.6
8.9–12.6ROR 10.6 · calibrated p 0.027 ✓
9.8 EB05 8.5 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=125 · 100% consumerno trial arm names this drug
Reversible cerebral vasoconstriction syndrome11810.1
8.4–12.2ROR 10.1 · calibrated p 0.032 ✓
9.4 EB05 8.0 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=118 · ♀ 100% (drug 72%) · 100% clinicianno trial arm names this drug
Hostility15410.1
8.6–11.9ROR 10.1 · calibrated p 0.032 ✓
9.4 EB05 8.2 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=135no trial arm names this drug
Personality disorder15810.1
8.6–11.9ROR 10.1 · calibrated p 0.032 ✓
9.4 EB05 8.2 · IC025 +3.0
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=149no trial arm names this drug
Clonus16410.1
8.6–11.8ROR 10.1 · calibrated p 0.032 ✓
9.4 EB05 8.2 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=161 · 100% clinicianno trial arm names this drug
Negative thoughts1739.9
8.5–11.5ROR 9.9 · calibrated p 0.034 ✓
9.3 EB05 8.1 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=87 · 100% consumerno trial arm names this drug
Anorgasmia1589.8
8.3–11.5ROR 9.8 · calibrated p 0.036 ✓
9.1 EB05 8.0 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=127 · 100% consumerno trial arm names this drug
Homicidal ideation2359.7
8.5–11.1ROR 9.7 · calibrated p 0.036 ✓
9.1 EB05 8.2 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=230no trial arm names this drug
Food allergy4349.7
8.8–10.6ROR 9.7 · calibrated p 0.036 ✓
9.1 EB05 8.4 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=422 · ♀ 100% (drug 72%)no trial arm names this drug
Small for dates baby2839.5
8.5–10.8ROR 9.6 · calibrated p 0.038 ✓
9.0 EB05 8.1 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=283no trial arm names this drug
Urinary tract disorder2459.1
8.0–10.4ROR 9.1 · calibrated p 0.044 ✓
8.6 EB05 7.7 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=241 · ♀ 0% (drug 72%)no trial arm names this drug
Mydriasis6828.9
8.2–9.6ROR 8.9 · calibrated p 0.047 ✓
8.4 EB05 7.9 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 7.9no trial arm names this drug
Suicide attempt3,2328.9
8.6–9.2ROR 9.1 · calibrated p 0.044 ✓
8.5 EB05 8.2 · IC025 +3.0
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 6.6 · serious PRR 6.6no trial arm names this drug
Hypomania1968.9
7.7–10.3ROR 8.9 · calibrated p 0.049 ✓
8.4 EB05 7.4 · IC025 +2.8
3/3 methods agree
Labeled — boxed warning
exact term
serious n=184no trial arm names this drug
Withdrawal syndrome2,1668.6
8.2–8.9ROR 8.7 · calibrated p 0.051
8.2 EB05 7.9 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 7.9 · serious PRR 6.2no trial arm names this drug
Psychomotor retardation1428.5
7.2–10.1ROR 8.5 · calibrated p 0.057
8.0 EB05 6.9 · IC025 +2.7
3/3 methods agree
Likely indication confounding
term in indications
serious n=140 · 100% clinicianno trial arm names this drug
Tearfulness2178.4
7.3–9.6ROR 8.4 · calibrated p 0.059
7.9 EB05 7.1 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=196no trial arm names this drug
Gestational diabetes2368.4
7.3–9.5ROR 8.4 · calibrated p 0.058
7.9 EB05 7.1 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=233 · ♀ 100% (drug 72%)no trial arm names this drug
Atrial septal defect4198.3
7.5–9.2ROR 8.3 · calibrated p 0.059
7.9 EB05 7.3 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious PRR 6.2no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality11,1677.57.4–7.7signal
Depression8,1544.74.6–4.8signal
Extrapyramidal2,3763.73.5–3.8signal
Dependence / withdrawal6,5583.63.5–3.7signal
Hyponatraemia1,4112.82.7–3.0signal
Seizure3,2752.72.6–2.8signal
Arrhythmia / qt2,5842.12.1–2.2signal
Fall / fracture4,9782.12.0–2.2signal
Rhabdomyolysis / myopathy1,0402.11.9–2.2raised
Pancreatitis1,0222.01.9–2.2raised
Hyperglycaemia / diabetes3,3121.51.5–1.6raised
Hypoglycaemia9121.51.4–1.6raised
Liver injury2,8451.51.5–1.6raised
Kidney injury4,0121.41.4–1.4raised
Tendon disorder3191.31.2–1.5raised
Venous thromboembolism1,7561.31.2–1.4raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Venlafaxine only as a background or rescue medication (NCT01360866, NCT01838681); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)9,9981.2
1.2–1.2ROR 1.2 · calibrated p 0.460
1.2 EB05 1.2 · IC025 +0.2Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Nausea9,1241.9
1.8–1.9ROR 1.9 · calibrated p 0.898
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.9no trial arm names this drug
Fatigue (tiredness)8,2041.7
1.7–1.7ROR 1.7 · calibrated p 0.792
1.7 EB05 1.7 · IC025 +0.7Likely indication confounding
term in indications; also in warnings
age-adj. PRR 1.5 · serious PRR 1.7no trial arm names this drug
Headache7,5061.9
1.9–2.0ROR 2.0 · calibrated p 0.932
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 2.2no trial arm names this drug
Dizziness6,5912.1
2.1–2.2ROR 2.2 · calibrated p 0.959
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.1no trial arm names this drug
Depression6,3524.5
4.4–4.6ROR 4.7 · calibrated p 0.268
4.4 EB05 4.3 · IC025 +2.1
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.8 · serious PRR 3.9no trial arm names this drug
Anxiety6,1723.5
3.4–3.6ROR 3.6 · calibrated p 0.455
3.4 EB05 3.4 · IC025 +1.7
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 3.0 · serious PRR 3.1no trial arm names this drug
Off label use (used outside approved label)6,1081.1
1.1–1.2ROR 1.1 · calibrated p 0.392
1.1 EB05 1.1 · IC025 +0.1Reporting / coding artifactage-adj. PRR 1.1 · serious PRR 1.3no trial arm names this drug
Pain5,5681.4
1.4–1.5ROR 1.5 · calibrated p 0.619
1.4 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.4no trial arm names this drug
Diarrhoea (diarrhea)5,3001.3
1.3–1.4ROR 1.3 · calibrated p 0.528
1.3 EB05 1.3 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.3no trial arm names this drug
Vomiting4,9171.7
1.6–1.7ROR 1.7 · calibrated p 0.772
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.5no trial arm names this drug
Insomnia (trouble sleeping)4,8662.9
2.9–3.0ROR 3.0 · calibrated p 0.620
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 2.4 · serious PRR 3.0no trial arm names this drug
Fall4,7512.3
2.2–2.4ROR 2.3 · calibrated p 0.882
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 1.9no trial arm names this drug
Toxicity to various agents4,6724.5
4.4–4.7ROR 4.7 · calibrated p 0.274
4.4 EB05 4.3 · IC025 +2.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.1 · serious PRR 3.5 · 94% clinicianno trial arm names this drug
Dyspnoea (shortness of breath)4,5801.3
1.3–1.3ROR 1.3 · calibrated p 0.510
1.3 EB05 1.3 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.2no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Venlafaxine (serotonergic antidepressants) ↔ Serotonin syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Venlafaxine?

In FDA FAERS, the most frequently co-reported reaction terms for Venlafaxine are nausea, fatigue, headache, dizziness, depression, anxiety. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Venlafaxine have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.

Do FAERS signals prove that Venlafaxine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.